Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.41 |
| ▸ | CCR6 | P51684 | 3/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
| ▸ | VEGFA | P15692 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12253065 | 0.94 | ALK (0.43) | PDE5AALKPGRTBXA2RCCR6 | |
| SCHEMBL2380877 | 0.87 | TBXA2R (0.44) | TBXA2RCCR6EPAS1ALDH1A1VEGFA | |
| SCHEMBL12317714 | 0.86 | TBXA2R (0.46) | TBXA2REPAS1VEGFAKMT2A | |
| SCHEMBL2379501 | 0.85 | ALDH1A1 (0.43) | TBXA2REPAS1ALDH1A1VEGFAKMT2A | |
| SCHEMBL692824 | 0.85 | ALDH1A1 (0.45) | TBXA2REPAS1ALDH1A1VEGFAKMT2A | |
| SCHEMBL2380749 | 0.84 | TBXA2R (0.46) | TBXA2RCCR6ALDH1A1KMT2AKDM4E | |
| SCHEMBL12253169 | 0.84 | CCR6 (0.38) | TBXA2RCCR6EPAS1ALDH1A1VEGFA | |
| SCHEMBL2379451 | 0.84 | CCR6 (0.49) | TBXA2RCCR6ALDH1A1KMT2APOLB | |
| SCHEMBL12304219 | 0.84 | DRD2 (0.45) | TBXA2REPAS1KMT2A | |
| SCHEMBL2379247 | 0.83 | SFRP1 (0.44) | CCR6EPAS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547655-B1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2547655-B1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20140221428-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221428-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221428-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741894-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741894-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741894-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2547655-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011116161-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011116161-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | PDE5A 1937/4885ALK 2208/4885PGR 3363/4885 |
| US-20140221428-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | PDE5A 1937/4885ALK 2208/4885PGR 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.